Buy Rainbow Childrens Medicare; target of Rs 1700: Emkay Global Financial

BUY

Emkay Global Financial's research report on Rainbow Childrens Medicare

Rainbow’s Q3FY25 print was largely in line with our estimates as revenue/EBITDA grew 18%/14% YoY, respectively. Ramp up in new hospitals remains strong with breakeven expected for Hyderabad hospitals (commissioned during Q4FY24) within the next quarter. Delay in commissioning of hospitals in the pipeline, however, was a slight dampener in our view. We believe the company has multiple margin levers that would offset the expected drag from its staggered bed expansion plans over FY25-27 as we anticipate EBITDA CAGR at 18%. Strong net cash balance sheet and robust cash conversion provide comfort on valuations. Baking in the delay in execution,

Outlook

We cut FY26/27E EBITDA by 3% and trim Dec-25E TP to Rs1,700 (5.6% cut) based on 29x Dec-26E pre-IndAS EV/EBITDA.

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Rainbow Childrens Medicare_11022025_Emkay